公开(公告)号：US20180243298A1

公开(公告)日：2018-08-30

申请号：US15563888

申请日：2016-03-30

Applicant: AbbVie Inc.

Inventor： Lawrence Black ,  Brian S. Brown ,  Bruce Clapham ,  Marlon D. Cowart ,  Michael J. Dart ,  Ramin Faghih ,  Jennifer Frost ,  Arthur R. Gomtsyan ,  Philip R. Kym ,  Huaqing Liu ,  Robert G. Schmidt ,  Lei Shi ,  Anurupa Shrestha ,  Kevin Sippy

IPC: A61K31/506 ,  A61P17/06 ,  A61P17/04

CPC classification number: A61K31/506 ,  A61P17/04 ,  A61P17/06 ,  C07D417/12 ,  C07D417/14 ,  C07D491/048 ,  C07D491/107

Abstract: A compound of Formula (I) having efficacy for the treatment or prevention of conditions and disorders related to TRPV3 activity, e.g. pain, atopic dermatitis, eczema, itch or psoriasis, is disclosed. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

公开(公告)号：US20130165479A1

公开(公告)日：2013-06-27

申请号：US13706468

申请日：2012-12-06

Applicant: AbbVie, Inc.

Inventor： Arthur R. Gomtsyan ,  Robert G. Schmidt, JR. ,  Jerome F. Daanen ,  Erol K. Bayburt ,  Chih-Hung Lee ,  Steven P. Latshaw

IPC: C07C275/26 ,  C07D311/04 ,  C07D215/22

CPC classification number: C07C275/32 ,  C07D215/12 ,  C07D215/42 ,  C07D215/54 ,  C07D311/58 ,  C07D311/74

Abstract: The present application is directed to compounds that are TRPV1 antagonictc and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

Abstract translation: 本申请涉及TRPV1拮抗剂并具有式（I）的化合物，其中变量Ar1，L1，R1，R2，R3，R4，R5，Y1，Y2和Y3如说明书中所定义，它们是有用的 用于治疗由香草素受体活性引起或加剧的病症。